Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review
Open Access
- 2 July 2022
- journal article
- review article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1-23
Abstract
Background: Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC. Methods: The Preferred Reported Items for Systematic reviews and Meta-Analyses guidelines was followed by applying a search strategy across six databases. All studies identified as economic evaluations with TARE for HCC treatment in English or Spanish language were considered. Costs were adjusted using the 2020 US dollars based on purchasing-power-parity ($US PPP). Results: Among 423 records screened, 20 studies (6 cost-analyses, 3 budget-impact-analyses, 2 cost-effectiveness-analyses, 8 cost-utility-analyses, and 1 cost-minimization analysis) met the pre-defined criteria for inclusion. Thirteen studies were published from the European perspective, six from the United States, and one from the Canadian perspectives. The assessed populations included early- (n = 4), and intermediate-advanced-stages patients (n = 15). Included studies were evaluated from a payer perspective (n = 20) and included both payer and social perspective (n = 2). TARE was compared with transarterial chemoembolization (TACE) in nine studies or sorafenib (n = 11). The life-years gained (LYG) differed by comparator: TARE versus TACE (range: 1.3 to 3.1), and TARE versus sorafenib (range: 1.1 to 2.53). Of the 20 studies, TARE was associated with lower treatment costs in ten studies. The cost of TARE treatment varied widely according to Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from 1311 $US PPP/month (BCLC-A) to 71,890 $US PPP/5-years time horizon (BCLC-C). The incremental cost-utility ratio for TARE versus TACE resulted in a 17,397 $US PPP/Quality-adjusted-Life-Years (QALY), and for TARE versus sorafenib ranged from dominant (more effectiveness and lower cost) to 3363 $US PPP/QALY. Conclusions: Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term therapy for the treatment of intermediate-advanced HCC.Keywords
This publication has 35 references indexed in Scilit:
- Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness AnalysisValue in Health, 2017
- BEYOND BUDGET SILOS: BUDGET IMPACT ANALYSIS OF TRANSARTERIAL RADIOEMBOLIZATION WITH YTTRIUM-90 GLASS MICROSPHERES FOR HEPATOCELLULAR CARCINOMA FROM A HOSPITAL PERSPECTIVEValue in Health, 2016
- Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver diseaseJournal of Gastroenterology and Hepatology, 2015
- Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centersTherapeutics and Clinical Risk Management, 2015
- Cost Effectiveness of Radioembolization Compared with Conventional Transarterial Chemoembolization for Treatment of Hepatocellular CarcinomaJournal of Vascular and Interventional Radiology, 2014
- Simulation study on cost-effectiveness of radioembolization compared with trans-arterial chemoembolization for hepatocellular carcinomaJournal of Vascular and Interventional Radiology, 2014
- Left-Liver Hypertrophy After Therapeutic Right-Liver Radioembolization Is Substantial but Less Than After Portal Vein EmbolizationHepatology, 2013
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statementThe European Journal of Health Economics, 2013
- Interventional Radiologic Treatment of Hepatocellular Carcinoma—A Cost Analysis from the Payer PerspectiveJournal of Vascular and Interventional Radiology, 2012
- Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitariasGaceta Sanitaria, 2010